A realistic goal is steady, medically appropriate weight loss while preserving strength and health
For comparison, semaglutide alone achieved approximately 14.9% in the STEP 1 trial, and tirzepatide achieved approximately 20.9% in SURMOUNT-1 at 72 weeks
Why Triple Agonism May Offer Unique Benefits Retatrutide distinguishes itself from other GLP-1 medications through its triple-agonist mechanism, simultaneously activating GLP-1, GIP, and glucagon receptors
The factors surrounding the peptide, including nutrition, sleep, stress management, and concurrent therapies, all influence outcomes
It mainly focuses on dark spots on your skin and makes it glow in a very short period